CD27 and hematologic disorder: Antigens such as CD27, CD37, CD70, CD80, CD86, B7-H3 and B7-H4, which are expressed in hematological malignancies and targeted by CAR-T cells, are promising candidates for clinical development [103,104,105] (Figure 2).